This year’s annual meeting of the American Society of Clinical Oncology (ASCO) came to an end yesterday in Chicago.

Monday was the busiest day with regard to myeloma-related research. The day started with an oral presentation session that in­cluded eight talks about im­por­tant new myeloma-related research. A poster session in the afternoon in­cluded several posters about myeloma-related research.

This article summarizes the most im­por­tant findings from Monday's oral pre­sen­ta­tion session. A later article will cover the findings from the after­noon poster session.

The content in our daily updates is based on the …

This year’s American Society of Clinical Oncology (ASCO) annual meeting, which is being held in Chicago, began on Friday and goes through Tuesday.

Sunday started with a poster session in which im­por­tant new re­search findings were summarized on posters dis­played throughout a large conference hall.

The stud­ies pre­sented during the session were on a wide variety of myeloma-related topics, in­clud­ing new treat­ments being devel­oped for myeloma, cur­rently used regi­mens, smol­der­ing mul­ti­ple myeloma, and findings on initial ther­apy.

Some of the posters in­cluded pre­lim­i­nary results from on­go­ing clin­i­cal trials.  Others described the design …

In a recent review article pub­lished in the journal Clinical Cancer Re­search, two myeloma experts from the Dana-Farber Cancer In­sti­tute, Dr. Nikhil Munshi and Dr. Kenneth Anderson, review the latest strategies in the treat­ment of mul­ti­ple myeloma.

In their article, the experts discuss newer ther­a­pies that appear to be promising in clin­i­cal and pre­clin­i­cal stud­ies.

According to the physicians, com­bi­na­tion ther­a­pies that spe­cif­i­cally target a patient’s ge­netic form of the dis­ease will be re­quired for long-term dis­ease con­trol and ultimately a cure.

Some Historical Perspective

In their review article, Drs. Munshi and …

A subanalysis of recent clinical trial results shows good response rates for single-agent Kyprolis in heavily pretreated multiple myeloma patients with high-risk chromosomal ab­nor­mal­i­ties.

Specifically, the investigators found that the response rates for patients with high-risk chromosomal ab­nor­mal­i­ties were similar to those for patients without high-risk chromosomal ab­nor­mal­i­ties.

However, the researchers also found that response duration and over­all survival remained significantly lower in patients with high-risk chromo­som­al ab­nor­mal­i­ties.

Nevertheless, the researchers describe the results as encouraging, and they suggest that treat­ment with Kyprolis (car­filz­o­mib) may be beneficial for patients with high-risk …

The American Society of Clinical Oncology will hold its 49^th annual meeting May 31 through June 4 in Chicago.

Similar to pre­vi­ous years, more than 25,000 clin­i­cal spe­cialists from all over the world are ex­pec­ted to attend the five-day meeting to discuss the cur­rent re­search in cancer treat­ment and care. The theme for this year’s meeting is “Building Bridges to Conquer Cancer.”

During the meeting, there will be pre­sen­ta­tions and seminars about all areas of cancer, in­clud­ing many focused spe­cif­i­cally on mul­ti­ple myeloma. The ASCO website cur­rently lists more than 60 myeloma-based pre­sen­ta­tions (included …

Los resultados iniciales de un ensayo clínico en marcha, en fase 2, muestran que Kyprolis en combinación con Revlimid y dexametasona a bajas dosis puede ser eficaz y seguro en pacientes con mieloma indolente de alto riesgo.

En concreto, los resultados muestran que todos los pacientes respondieron a la terapia combinada y que el 75 por ciento de ellos consiguieron por lo menos una remisión casi completa.

No se dispone todavía de cifras de progresión libre de enfermedad o de supervivencia global, por lo que aún no se sabe si la terapia …

A subgroup analysis of recent Phase 1/2 clinical trial results shows that Kyprolis in com­bi­na­tion with Revlimid and low-dose dexa­meth­a­sone is effective and well tolerated in newly diagnosed multiple myeloma patients over the age of 65.

All of the evaluated patients responded to treat­ment, with 83 per­cent of patients reaching at least a near complete response.

According to Dr. Andrzei Jakubowiak of the University of Chicago Medical Center, who presented the findings earlier this month at the Inter­na­tional Myeloma Workshop (IMW) in Kyoto, Japan, the response rates compare favorably to the best …